|Articles|February 15, 2002
- BioPharm International-02-01-2002
- Volume 15
- Issue 2
21 CFR Part 11: (Un)Expected Added Value
By Joseph F. Noferi, Esq., Ralph Dillon, and Daniel E. Worden, pp. 44-50. Implementing the ERES rule will do more than make your organization compliant with federal regulations. It will strengthen its intellectual property position for the information age.
Advertisement
Articles in this issue
almost 24 years ago
Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Baralmost 24 years ago
Outsourcing Outlook: Reaping the Benefits of E-Procurementalmost 24 years ago
The Immunogenicity of Therapeutic Proteinsalmost 24 years ago
Analytical Advances: Calibration Management of Outsourced Calibrationsalmost 24 years ago
Inside Washington: Costs and Controls Challenge ManufacturersNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Formulation Strategies, Tech Advances, Challenges, and Considerations in Novel Drug Delivery
2
BioPharm Weekly News Roundup—Week of Nov. 24, 2025
3
Op-Ed: Why the US Must Move Beyond Its mRNA Monoculture
4
What a $2 Billion Maryland Expansion Means for the Future of Biologics Production
5
